A phase IIb trial to evaluate the efficacy and safety of intranasal oxytocin (TI-001) in patients with migraine

Trial Profile

A phase IIb trial to evaluate the efficacy and safety of intranasal oxytocin (TI-001) in patients with migraine

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2016 New trial record
    • 30 Mar 2016 According to a Trigemina media release, this trial is expected to start later this year 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top